Your Shopping Cart Is Empty
| ✷ Report Code: A00423 | Feb 2022 | Pages: 270 | ||
| Tables: 141 | Charts: 62 |
| |
Pandemic disrupted the entire world and affected many industries.
Get detailed COVID-19 impact analysis on the Metabolomics Market
Request Now !The global metabolomics market size was valued at $2,032 Million in 2020, and is projected to reach $6,663 Million by 2030, registering a CAGR of 12.2% from 2021 to 2030. Metabolomics is the study and analysis of the biochemical processes involving intermediates and byproducts of metabolic activities. These products are known as metabolomes, which reflect the cluster of all metabolites involved in various reactions in an organism, which include metabolic intermediates, signaling molecules, secondary metabolites, and hormones. Metabolomics includes the utilization of various analytical techniques for the determination of metabolites such as, spectroscopy, chromatography, and multivariate analysis. Metabolites are closely related to the phenotype of an organism, and can be used for a wide range of applications such as, substantial equivalence testing, phenotyping of genetically modified plants, identification of gene function, and biotic-abiotic stress reaction analysis.
It facilitates researchers and scientists to calculate physiological effects and observe adverse reaction of drugs on an organism. The global metabolomics market is driven by increase in adoption of metabolomics in precision medicine and advent of diagnostics tests for diagnosis of chronic diseases. Moreover, technological advancements in analytical techniques and upsurge in R&D expenditure are expected to boost the market growth.
Furthermore, metabolomics has the ability to detect a large number of metabolites from fluid or tissue sample in a single step and it also can yield great amounts, which leads to rise in demand for metabolomics thereby driving the growth of the market. Nuclear magnetic resonance spectroscopy (NMR) and mass spectrometry (MS) are the most common analytical techniques employed for metabolomics applications. Currently, a variety of techniques within these two technological fields is being developed to deal with the type of sophisticated samples examined in metabolomics studies. Owing to such remarkable recognition abilities metabolomics promises huge potential in disease diagnosis, prognosis, and therapeutic development.
Restraints for metabolomics market are high cost of metabolomic instruments and scarcity of professionals. Top notch analytical and separations devices are very expensive as the cost of raw materials and manufacturing costs of such equipment’s is very high. For instance, the cost for mass spectrometry and high-performance liquid chromatography devices ranges between million and thousand dollars per device, high cost of metabolomics instruments can slow down the growth of the market in developing and underdeveloped areas as even commercial buyers would be incapable of purchasing such equipment, which in turn hampers the applications of metabolomics technology.
Smart pricing strategy is anticipated to increase the customer base; thereby, positively impacting the growth of the global metabolomics market. Opportunities for metabolomic market are immense in disease diagnosis. Early detection of chronic diseases allows healthcare providers to plan for effective disease treatment, thereby improving patient survival rate and aiding in the complete elimination of the disease from patient’s biological system.
The World Health Organization (WHO) on January 30, 2020 declared COVID-19 flare-up a general wellbeing crisis of international concern. Coronavirus has impacted around 210 countries across the globe. Owing to the COVID-19 pandemic, state run administrations across the globe declared inescapable lockdowns as well as friendly distancing measures to forestall breakdown of the healthcare structure. States have additionally given constraints and preventions on undertakings and elective surgeries. These deterrents continue to influence the growth of various industries, and the speedy impact of the episode changes starting with one industry then onto the following. The scattering, production, and store network have been impacted, due to execution of lockdown across the globe.
COVID-19 has had a positive impact on the metabolomics market. This is due to the fact that metabolomics is applied in research for understanding the diseases, COVDI-19. For instance, alterations in the plasma metabolone reflect the clinical presentation of COVID-19 patients in mild, moderate, and critical COVID-19 cases. The alterations revealed major stage-associated shifts in the metabolome, at least 77 metabolites including amino acids, lipids, polyamines & sugars, as well as their derivatives, were altered in critical COVID-19 patient’s plasma as compared to mild COVID-19 patients. Hence, this led to surge in applications of metabolomics in COVID-19 related research thereby leading to a positive impact on the metabolomics market.
The metabolomics market is segmented based on product & service, application, indication, and region. Based on product & service, it is divided into metabolomics instruments and metabolomics bioinformatics tools & services. The metabolomics instruments segment is further divided into separation techniques and detection techniques. The separation techniques segment is further classified into high-performance liquid chromatography, gas chromatography, ultra-performance liquid chromatography, and capillary electrophoresis. The detection techniques segment is further categorized into mass spectrometry, nuclear magnetic resonance spectroscopy, and surface-based mass analysis.
The metabolomics bioinformatics tools & services segment is further bifurcated into bioinformatics tools & databases and bioinformatics services. Based on application, the metabolomics market is categorized into biomarker discovery, drug discovery, toxicology testing, nutrigenomics, functional genomics, personalized medicine, and others. Based on indication, it is divided into cancer, cardiovascular disorders, neurological disorders, inborn errors of metabolism, and others. On the basis of region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
By product segment the largest market for metabolomics is metabolomics bioinformatics due to a huge number of utilization in metabolomics analysis tool and services and due to increasing demand for data management it is anticipated to grow at the highest CAGR during the forecast period.
By application segment the largest market in metabolomics is biomarker discovery as technological advancement in discovery technologies, an upsurge in incidences of chronic diseases, and increase in demand for personalized healthcare and growth in recognitions for modern diagnostics tests the personalized medicine market is anticipated to grow at the highest CAGR during the forecast period.
By indication segment, the largest market for metabolomics is for cancer as metabolomics is widely being developed in oncology sector and it is projected to drive the cancer segment and neurological disorder market is anticipated to grow at the highest CAGR during the forecast period.
By region North America is the largest metabolomics market and Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period.
The key players operating in the global Metabolomics market include Agilent Technologies INC., BiocratesLife Science AG, Bio-Rad Laboratories INC., Bruker corporation, Danaher Corporation, Human Metabolome Technologies INC., LECO Corporation, Metabolon INC., Shimadzu Corporation, Water Corporation.
Key Benefits for Stakeholders
Metabolomics Market Report Highlights
| Aspects | Details |
|---|---|
| By PRODUCT AND SERVICES |
|
| By APPLICATION |
|
| By INDICATION |
|
| By Region |
|
| Key Market Players | Human Metabolome Technologies, Inc., Bio-Rad Laboratories, Inc., Shimadzu Corporation, Biocrates Life Sciences AG, Danaher Corporation, Metabolon, Inc., Agilent Technologies, Inc., LECO Corporation, Bruker Corporation, Waters Corporation |
CHAPTER 1:INTRODUCTION
1.1.Report Description
1.2.Key Market Segments
1.3.Key Benefits
1.4.Research Methodology
1.4.1.Primary Research
1.4.2.Secondary Research
1.4.3.Analyst Tools and Models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.CXO Perspective
CHAPTER 3:MARKET LANDSCAPE
3.1.Market Definition and Scope
3.2.Key Findings
3.2.1.Top Investment Pockets
3.2.2.Top Winning Strategies
3.3.Porter's Five Forces Analysis
3.3.1.Bargaining Power of Suppliers
3.3.2.Threat of New Entrants
3.3.3.Threat of Substitutes
3.3.4.Competitive Rivalry
3.3.5.Bargaining Power among Buyers
3.4.Market Share Analysis/Top Player Positioning
3.4.1. Market Share Analysis/Top Player Positioning 2020
3.5.Market Dynamics
3.5.1. Drivers
3.5.2. Restraints
3.5.3. Opportunities
3.6.COVID-19 Impact Analysis
CHAPTER 4:METABOLOMICS MARKET, BY PRODUCT AND SERVICES
4.1.Market Overview
4.1.1Market Size and Forecast, By Product And Services
4.2. Metabolomics Instruments
4.2.1.Key Market Trends, Growth Factors and Opportunities
4.2.2.Market Size and Forecast, By Region
4.2.3.Market Share Analysis, By Country
4.2.4.Separation Tools
4.2.4.1.Market Size and Forecast
4.2.5.2.High-Performance Liquid Chromatography
4.2.5.2.1.Market Size and Forecast
4.2.5.2.Gas Chromatography
4.2.5.2.1.Market Size and Forecast
4.2.5.2.Ultra Performance Liquid Chromatography
4.2.5.2.1.Market Size and Forecast
4.2.5.2.Capillary Electrophoresis
4.2.5.2.1.Market Size and Forecast
4.2.5.Detection Tools
4.2.5.1.Market Size and Forecast
4.2.6.2.Mass Spectrometry
4.2.6.2.1.Market Size and Forecast
4.2.6.2.Nuclear Magnetic Resonance Spectroscopy
4.2.6.2.1.Market Size and Forecast
4.2.6.2.Surface-Based Mass Analysis
4.2.6.2.1.Market Size and Forecast
4.3. Metabolomics Bioinformatics Tools And Services
4.3.1.Key Market Trends, Growth Factors and Opportunities
4.3.2.Market Size and Forecast, By Region
4.3.3.Market Share Analysis, By Country
4.3.4.Bioinformatics Tools
4.3.4.1.Market Size and Forecast
4.3.5.Databases and Bioinformatics Services
4.3.5.1.Market Size and Forecast
CHAPTER 5:METABOLOMICS MARKET, BY APPLICATION
5.1.Market Overview
5.1.1Market Size and Forecast, By Application
5.2. Biomarker Discovery
5.2.1.Key Market Trends, Growth Factors and Opportunities
5.2.2.Market Size and Forecast, By Region
5.2.3.Market Share Analysis, By Country
5.3. Drug Discovery
5.3.1.Key Market Trends, Growth Factors and Opportunities
5.3.2.Market Size and Forecast, By Region
5.3.3.Market Share Analysis, By Country
5.4. Toxicology Testing
5.4.1.Key Market Trends, Growth Factors and Opportunities
5.4.2.Market Size and Forecast, By Region
5.4.3.Market Share Analysis, By Country
5.5. Nutrigenomics
5.5.1.Key Market Trends, Growth Factors and Opportunities
5.5.2.Market Size and Forecast, By Region
5.5.3.Market Share Analysis, By Country
5.6. Functional Genomics
5.6.1.Key Market Trends, Growth Factors and Opportunities
5.6.2.Market Size and Forecast, By Region
5.6.3.Market Share Analysis, By Country
5.7. Personalized Medicine
5.7.1.Key Market Trends, Growth Factors and Opportunities
5.7.2.Market Size and Forecast, By Region
5.7.3.Market Share Analysis, By Country
5.8. Other Applications
5.8.1.Key Market Trends, Growth Factors and Opportunities
5.8.2.Market Size and Forecast, By Region
5.8.3.Market Share Analysis, By Country
CHAPTER 6:METABOLOMICS MARKET, BY INDICATION
6.1.Market Overview
6.1.1Market Size and Forecast, By Indication
6.2. Cancer
6.2.1.Key Market Trends, Growth Factors and Opportunities
6.2.2.Market Size and Forecast, By Region
6.2.3.Market Share Analysis, By Country
6.3. Cardiovascular Disorders
6.3.1.Key Market Trends, Growth Factors and Opportunities
6.3.2.Market Size and Forecast, By Region
6.3.3.Market Share Analysis, By Country
6.4. Neurological Disorders
6.4.1.Key Market Trends, Growth Factors and Opportunities
6.4.2.Market Size and Forecast, By Region
6.4.3.Market Share Analysis, By Country
6.5. Inborn Errors Of Metabolism
6.5.1.Key Market Trends, Growth Factors and Opportunities
6.5.2.Market Size and Forecast, By Region
6.5.3.Market Share Analysis, By Country
6.6. Other Indications
6.6.1.Key Market Trends, Growth Factors and Opportunities
6.6.2.Market Size and Forecast, By Region
6.6.3.Market Share Analysis, By Country
CHAPTER 7:METABOLOMICS MARKET, BY REGION
7.1.Market Overview
7.1.1Market Size and Forecast, By Region
7.2.North America
7.2.1.Key Market Trends and Opportunities
7.2.2.Market Size and Forecast, By Product And Services
7.2.3.Market Size and Forecast, By Application
7.2.4.Market Size and Forecast, By Indication
7.2.5.Market Size and Forecast, By Country
7.2.6.United States Metabolomics Market
7.2.6.1.Market Size and Forecast, By Product And Services
7.2.6.2.Market Size and Forecast, By Application
7.2.6.3.Market Size and Forecast, By Indication
7.2.7.Canada Metabolomics Market
7.2.7.1.Market Size and Forecast, By Product And Services
7.2.7.2.Market Size and Forecast, By Application
7.2.7.3.Market Size and Forecast, By Indication
7.2.8.Mexico Metabolomics Market
7.2.8.1.Market Size and Forecast, By Product And Services
7.2.8.2.Market Size and Forecast, By Application
7.2.8.3.Market Size and Forecast, By Indication
7.3.Europe
7.3.1.Key Market Trends and Opportunities
7.3.2.Market Size and Forecast, By Product And Services
7.3.3.Market Size and Forecast, By Application
7.3.4.Market Size and Forecast, By Indication
7.3.5.Market Size and Forecast, By Country
7.3.6.Germany Metabolomics Market
7.3.6.1.Market Size and Forecast, By Product And Services
7.3.6.2.Market Size and Forecast, By Application
7.3.6.3.Market Size and Forecast, By Indication
7.3.7.France Metabolomics Market
7.3.7.1.Market Size and Forecast, By Product And Services
7.3.7.2.Market Size and Forecast, By Application
7.3.7.3.Market Size and Forecast, By Indication
7.3.8.Uk Metabolomics Market
7.3.8.1.Market Size and Forecast, By Product And Services
7.3.8.2.Market Size and Forecast, By Application
7.3.8.3.Market Size and Forecast, By Indication
7.3.9.Italy Metabolomics Market
7.3.9.1.Market Size and Forecast, By Product And Services
7.3.9.2.Market Size and Forecast, By Application
7.3.9.3.Market Size and Forecast, By Indication
7.3.10.Spain Metabolomics Market
7.3.10.1.Market Size and Forecast, By Product And Services
7.3.10.2.Market Size and Forecast, By Application
7.3.10.3.Market Size and Forecast, By Indication
7.3.11.Rest Of Europe Metabolomics Market
7.3.11.1.Market Size and Forecast, By Product And Services
7.3.11.2.Market Size and Forecast, By Application
7.3.11.3.Market Size and Forecast, By Indication
7.4.Asia-Pacific
7.4.1.Key Market Trends and Opportunities
7.4.2.Market Size and Forecast, By Product And Services
7.4.3.Market Size and Forecast, By Application
7.4.4.Market Size and Forecast, By Indication
7.4.5.Market Size and Forecast, By Country
7.4.6.Japan Metabolomics Market
7.4.6.1.Market Size and Forecast, By Product And Services
7.4.6.2.Market Size and Forecast, By Application
7.4.6.3.Market Size and Forecast, By Indication
7.4.7.China Metabolomics Market
7.4.7.1.Market Size and Forecast, By Product And Services
7.4.7.2.Market Size and Forecast, By Application
7.4.7.3.Market Size and Forecast, By Indication
7.4.8.Australia Metabolomics Market
7.4.8.1.Market Size and Forecast, By Product And Services
7.4.8.2.Market Size and Forecast, By Application
7.4.8.3.Market Size and Forecast, By Indication
7.4.9.India Metabolomics Market
7.4.9.1.Market Size and Forecast, By Product And Services
7.4.9.2.Market Size and Forecast, By Application
7.4.9.3.Market Size and Forecast, By Indication
7.4.10.South Korea Metabolomics Market
7.4.10.1.Market Size and Forecast, By Product And Services
7.4.10.2.Market Size and Forecast, By Application
7.4.10.3.Market Size and Forecast, By Indication
7.4.11.Rest Of Asia-pacific Metabolomics Market
7.4.11.1.Market Size and Forecast, By Product And Services
7.4.11.2.Market Size and Forecast, By Application
7.4.11.3.Market Size and Forecast, By Indication
7.5.LAMEA
7.5.1.Key Market Trends and Opportunities
7.5.2.Market Size and Forecast, By Product And Services
7.5.3.Market Size and Forecast, By Application
7.5.4.Market Size and Forecast, By Indication
7.5.5.Market Size and Forecast, By Country
7.5.6.Brazil Metabolomics Market
7.5.6.1.Market Size and Forecast, By Product And Services
7.5.6.2.Market Size and Forecast, By Application
7.5.6.3.Market Size and Forecast, By Indication
7.5.7.Saudi Arabia Metabolomics Market
7.5.7.1.Market Size and Forecast, By Product And Services
7.5.7.2.Market Size and Forecast, By Application
7.5.7.3.Market Size and Forecast, By Indication
7.5.8.South Africa Metabolomics Market
7.5.8.1.Market Size and Forecast, By Product And Services
7.5.8.2.Market Size and Forecast, By Application
7.5.8.3.Market Size and Forecast, By Indication
7.5.9.Rest of LAMEA Metabolomics Market
7.5.9.1.Market Size and Forecast, By Product And Services
7.5.9.2.Market Size and Forecast, By Application
7.5.9.3.Market Size and Forecast, By Indication
CHAPTER 8:COMPANY PROFILES
8.1. Agilent Technologies, Inc.
8.1.1.Company Overview
8.1.2.Key Executives
8.1.3.Company snapshot
8.1.4.Operating business segments
8.1.5.Product portfolio
8.1.6.Business Performance
8.1.7.Key Strategic Moves and Developments
8.2. Danaher Corporation
8.2.1.Company Overview
8.2.2.Key Executives
8.2.3.Company snapshot
8.2.4.Operating business segments
8.2.5.Product portfolio
8.2.6.Business Performance
8.2.7.Key Strategic Moves and Developments
8.3. Biocrates Life Sciences AG
8.3.1.Company Overview
8.3.2.Key Executives
8.3.3.Company snapshot
8.3.4.Operating business segments
8.3.5.Product portfolio
8.3.6.Business Performance
8.3.7.Key Strategic Moves and Developments
8.4. Bruker Corporation
8.4.1.Company Overview
8.4.2.Key Executives
8.4.3.Company snapshot
8.4.4.Operating business segments
8.4.5.Product portfolio
8.4.6.Business Performance
8.4.7.Key Strategic Moves and Developments
8.5. LECO Corporation
8.5.1.Company Overview
8.5.2.Key Executives
8.5.3.Company snapshot
8.5.4.Operating business segments
8.5.5.Product portfolio
8.5.6.Business Performance
8.5.7.Key Strategic Moves and Developments
8.6. Metabolon, Inc.
8.6.1.Company Overview
8.6.2.Key Executives
8.6.3.Company snapshot
8.6.4.Operating business segments
8.6.5.Product portfolio
8.6.6.Business Performance
8.6.7.Key Strategic Moves and Developments
8.7. Human Metabolome Technologies, Inc.
8.7.1.Company Overview
8.7.2.Key Executives
8.7.3.Company snapshot
8.7.4.Operating business segments
8.7.5.Product portfolio
8.7.6.Business Performance
8.7.7.Key Strategic Moves and Developments
8.8. Bio-Rad Laboratories, Inc.
8.8.1.Company Overview
8.8.2.Key Executives
8.8.3.Company snapshot
8.8.4.Operating business segments
8.8.5.Product portfolio
8.8.6.Business Performance
8.8.7.Key Strategic Moves and Developments
8.9. Shimadzu Corporation
8.9.1.Company Overview
8.9.2.Key Executives
8.9.3.Company snapshot
8.9.4.Operating business segments
8.9.5.Product portfolio
8.9.6.Business Performance
8.9.7.Key Strategic Moves and Developments
8.10. Waters Corporation
8.10.1.Company Overview
8.10.2.Key Executives
8.10.3.Company snapshot
8.10.4.Operating business segments
8.10.5.Product portfolio
8.10.6.Business Performance
8.10.7.Key Strategic Moves and Developments
LIST OF TABLES
TABLE 1.GLOBAL METABOLOMICS MARKET, BY PRODUCT AND SERVICES, 2020-2030 ($MILLION)
TABLE 2.GLOBAL METABOLOMICS MARKET FOR METABOLOMICS INSTRUMENTS, BY REGION, 2020-2030 ($MILLION)
TABLE 3.GLOBAL METABOLOMICS MARKET FOR METABOLOMICS BIOINFORMATICS TOOLS AND SERVICES, BY REGION, 2020-2030 ($MILLION)
TABLE 4.GLOBAL METABOLOMICS MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 5.GLOBAL METABOLOMICS MARKET FOR BIOMARKER DISCOVERY, BY REGION, 2020-2030 ($MILLION)
TABLE 6.GLOBAL METABOLOMICS MARKET FOR DRUG DISCOVERY, BY REGION, 2020-2030 ($MILLION)
TABLE 7.GLOBAL METABOLOMICS MARKET FOR TOXICOLOGY TESTING, BY REGION, 2020-2030 ($MILLION)
TABLE 8.GLOBAL METABOLOMICS MARKET FOR NUTRIGENOMICS, BY REGION, 2020-2030 ($MILLION)
TABLE 9.GLOBAL METABOLOMICS MARKET FOR FUNCTIONAL GENOMICS, BY REGION, 2020-2030 ($MILLION)
TABLE 10.GLOBAL METABOLOMICS MARKET FOR PERSONALIZED MEDICINE, BY REGION, 2020-2030 ($MILLION)
TABLE 11.GLOBAL METABOLOMICS MARKET FOR OTHER APPLICATIONS, BY REGION, 2020-2030 ($MILLION)
TABLE 12.GLOBAL METABOLOMICS MARKET, BY INDICATION, 2020-2030 ($MILLION)
TABLE 13.GLOBAL METABOLOMICS MARKET FOR CANCER, BY REGION, 2020-2030 ($MILLION)
TABLE 14.GLOBAL METABOLOMICS MARKET FOR CARDIOVASCULAR DISORDERS, BY REGION, 2020-2030 ($MILLION)
TABLE 15.GLOBAL METABOLOMICS MARKET FOR NEUROLOGICAL DISORDERS, BY REGION, 2020-2030 ($MILLION)
TABLE 16.GLOBAL METABOLOMICS MARKET FOR INBORN ERRORS OF METABOLISM, BY REGION, 2020-2030 ($MILLION)
TABLE 17.GLOBAL METABOLOMICS MARKET FOR OTHER INDICATIONS, BY REGION, 2020-2030 ($MILLION)
TABLE 18.GLOBAL METABOLOMICS MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 19.NORTH AMERICA METABOLOMICS, BY Region, 2020-2030 ($MILLION)
TABLE 20.NORTH AMERICA METABOLOMICS, BY PRODUCT AND SERVICES, 2020-2030 ($MILLION)
TABLE 21.NORTH AMERICA METABOLOMICS, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 22.NORTH AMERICA METABOLOMICS, BY INDICATION, 2020-2030 ($MILLION)
TABLE 23.UNITED STATES METABOLOMICS, BY PRODUCT AND SERVICES, 2020-2030 ($MILLION)
TABLE 24.UNITED STATES METABOLOMICS, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 25.UNITED STATES METABOLOMICS, BY INDICATION, 2020-2030 ($MILLION)
TABLE 26.CANADA METABOLOMICS, BY PRODUCT AND SERVICES, 2020-2030 ($MILLION)
TABLE 27.CANADA METABOLOMICS, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 28.CANADA METABOLOMICS, BY INDICATION, 2020-2030 ($MILLION)
TABLE 29.MEXICO METABOLOMICS, BY PRODUCT AND SERVICES, 2020-2030 ($MILLION)
TABLE 30.MEXICO METABOLOMICS, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 31.MEXICO METABOLOMICS, BY INDICATION, 2020-2030 ($MILLION)
TABLE 32.EUROPE METABOLOMICS, BY Region, 2020-2030 ($MILLION)
TABLE 33.EUROPE METABOLOMICS, BY PRODUCT AND SERVICES, 2020-2030 ($MILLION)
TABLE 34.EUROPE METABOLOMICS, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 35.EUROPE METABOLOMICS, BY INDICATION, 2020-2030 ($MILLION)
TABLE 36.GERMANY METABOLOMICS, BY PRODUCT AND SERVICES, 2020-2030 ($MILLION)
TABLE 37.GERMANY METABOLOMICS, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 38.GERMANY METABOLOMICS, BY INDICATION, 2020-2030 ($MILLION)
TABLE 39.FRANCE METABOLOMICS, BY PRODUCT AND SERVICES, 2020-2030 ($MILLION)
TABLE 40.FRANCE METABOLOMICS, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 41.FRANCE METABOLOMICS, BY INDICATION, 2020-2030 ($MILLION)
TABLE 42.UK METABOLOMICS, BY PRODUCT AND SERVICES, 2020-2030 ($MILLION)
TABLE 43.UK METABOLOMICS, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 44.UK METABOLOMICS, BY INDICATION, 2020-2030 ($MILLION)
TABLE 45.ITALY METABOLOMICS, BY PRODUCT AND SERVICES, 2020-2030 ($MILLION)
TABLE 46.ITALY METABOLOMICS, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 47.ITALY METABOLOMICS, BY INDICATION, 2020-2030 ($MILLION)
TABLE 48.SPAIN METABOLOMICS, BY PRODUCT AND SERVICES, 2020-2030 ($MILLION)
TABLE 49.SPAIN METABOLOMICS, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 50.SPAIN METABOLOMICS, BY INDICATION, 2020-2030 ($MILLION)
TABLE 51.REST OF EUROPE METABOLOMICS, BY PRODUCT AND SERVICES, 2020-2030 ($MILLION)
TABLE 52.REST OF EUROPE METABOLOMICS, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 53.REST OF EUROPE METABOLOMICS, BY INDICATION, 2020-2030 ($MILLION)
TABLE 54.ASIA-PACIFIC METABOLOMICS, BY Region, 2020-2030 ($MILLION)
TABLE 55.ASIA-PACIFIC METABOLOMICS, BY PRODUCT AND SERVICES, 2020-2030 ($MILLION)
TABLE 56.ASIA-PACIFIC METABOLOMICS, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 57.ASIA-PACIFIC METABOLOMICS, BY INDICATION, 2020-2030 ($MILLION)
TABLE 58.JAPAN METABOLOMICS, BY PRODUCT AND SERVICES, 2020-2030 ($MILLION)
TABLE 59.JAPAN METABOLOMICS, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 60.JAPAN METABOLOMICS, BY INDICATION, 2020-2030 ($MILLION)
TABLE 61.CHINA METABOLOMICS, BY PRODUCT AND SERVICES, 2020-2030 ($MILLION)
TABLE 62.CHINA METABOLOMICS, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 63.CHINA METABOLOMICS, BY INDICATION, 2020-2030 ($MILLION)
TABLE 64.AUSTRALIA METABOLOMICS, BY PRODUCT AND SERVICES, 2020-2030 ($MILLION)
TABLE 65.AUSTRALIA METABOLOMICS, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 66.AUSTRALIA METABOLOMICS, BY INDICATION, 2020-2030 ($MILLION)
TABLE 67.INDIA METABOLOMICS, BY PRODUCT AND SERVICES, 2020-2030 ($MILLION)
TABLE 68.INDIA METABOLOMICS, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 69.INDIA METABOLOMICS, BY INDICATION, 2020-2030 ($MILLION)
TABLE 70.SOUTH KOREA METABOLOMICS, BY PRODUCT AND SERVICES, 2020-2030 ($MILLION)
TABLE 71.SOUTH KOREA METABOLOMICS, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 72.SOUTH KOREA METABOLOMICS, BY INDICATION, 2020-2030 ($MILLION)
TABLE 73.REST OF ASIA-PACIFIC METABOLOMICS, BY PRODUCT AND SERVICES, 2020-2030 ($MILLION)
TABLE 74.REST OF ASIA-PACIFIC METABOLOMICS, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 75.REST OF ASIA-PACIFIC METABOLOMICS, BY INDICATION, 2020-2030 ($MILLION)
TABLE 76.LAMEA METABOLOMICS, BY Region, 2020-2030 ($MILLION)
TABLE 77.LAMEA METABOLOMICS, BY PRODUCT AND SERVICES, 2020-2030 ($MILLION)
TABLE 78.LAMEA METABOLOMICS, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 79.LAMEA METABOLOMICS, BY INDICATION, 2020-2030 ($MILLION)
TABLE 80.BRAZIL METABOLOMICS, BY PRODUCT AND SERVICES, 2020-2030 ($MILLION)
TABLE 81.BRAZIL METABOLOMICS, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 82.BRAZIL METABOLOMICS, BY INDICATION, 2020-2030 ($MILLION)
TABLE 83.SAUDI ARABIA METABOLOMICS, BY PRODUCT AND SERVICES, 2020-2030 ($MILLION)
TABLE 84.SAUDI ARABIA METABOLOMICS, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 85.SAUDI ARABIA METABOLOMICS, BY INDICATION, 2020-2030 ($MILLION)
TABLE 86.SOUTH AFRICA METABOLOMICS, BY PRODUCT AND SERVICES, 2020-2030 ($MILLION)
TABLE 87.SOUTH AFRICA METABOLOMICS, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 88.SOUTH AFRICA METABOLOMICS, BY INDICATION, 2020-2030 ($MILLION)
TABLE 89.REST OF LAMEA METABOLOMICS, BY PRODUCT AND SERVICES, 2020-2030 ($MILLION)
TABLE 90.REST OF LAMEA METABOLOMICS, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 91.REST OF LAMEA METABOLOMICS, BY INDICATION, 2020-2030 ($MILLION)
TABLE 92.AGILENT TECHNOLOGIES, INC.: KEY EXECUTIVES
TABLE 93.AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT
TABLE 94.AGILENT TECHNOLOGIES, INC.: OPERATING SEGMENTS
TABLE 95.AGILENT TECHNOLOGIES, INC.: PRODUCT PORTFOLIO
TABLE 96.AGILENT TECHNOLOGIES, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 97.DANAHER CORPORATION: KEY EXECUTIVES
TABLE 98.DANAHER CORPORATION: COMPANY SNAPSHOT
TABLE 99.DANAHER CORPORATION: OPERATING SEGMENTS
TABLE 100.DANAHER CORPORATION: PRODUCT PORTFOLIO
TABLE 101.DANAHER CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 102.BIOCRATES LIFE SCIENCES AG: KEY EXECUTIVES
TABLE 103.BIOCRATES LIFE SCIENCES AG: COMPANY SNAPSHOT
TABLE 104.BIOCRATES LIFE SCIENCES AG: OPERATING SEGMENTS
TABLE 105.BIOCRATES LIFE SCIENCES AG: PRODUCT PORTFOLIO
TABLE 106.BIOCRATES LIFE SCIENCES AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 107.BRUKER CORPORATION: KEY EXECUTIVES
TABLE 108.BRUKER CORPORATION: COMPANY SNAPSHOT
TABLE 109.BRUKER CORPORATION: OPERATING SEGMENTS
TABLE 110.BRUKER CORPORATION: PRODUCT PORTFOLIO
TABLE 111.BRUKER CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 112.LECO CORPORATION: KEY EXECUTIVES
TABLE 113.LECO CORPORATION: COMPANY SNAPSHOT
TABLE 114.LECO CORPORATION: OPERATING SEGMENTS
TABLE 115.LECO CORPORATION: PRODUCT PORTFOLIO
TABLE 116.LECO CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 117.METABOLON, INC.: KEY EXECUTIVES
TABLE 118.METABOLON, INC.: COMPANY SNAPSHOT
TABLE 119.METABOLON, INC.: OPERATING SEGMENTS
TABLE 120.METABOLON, INC.: PRODUCT PORTFOLIO
TABLE 121.METABOLON, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 122.HUMAN METABOLOME TECHNOLOGIES, INC.: KEY EXECUTIVES
TABLE 123.HUMAN METABOLOME TECHNOLOGIES, INC.: COMPANY SNAPSHOT
TABLE 124.HUMAN METABOLOME TECHNOLOGIES, INC.: OPERATING SEGMENTS
TABLE 125.HUMAN METABOLOME TECHNOLOGIES, INC.: PRODUCT PORTFOLIO
TABLE 126.HUMAN METABOLOME TECHNOLOGIES, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 127.BIO-RAD LABORATORIES, INC.: KEY EXECUTIVES
TABLE 128.BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT
TABLE 129.BIO-RAD LABORATORIES, INC.: OPERATING SEGMENTS
TABLE 130.BIO-RAD LABORATORIES, INC.: PRODUCT PORTFOLIO
TABLE 131.BIO-RAD LABORATORIES, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 132.SHIMADZU CORPORATION: KEY EXECUTIVES
TABLE 133.SHIMADZU CORPORATION: COMPANY SNAPSHOT
TABLE 134.SHIMADZU CORPORATION: OPERATING SEGMENTS
TABLE 135.SHIMADZU CORPORATION: PRODUCT PORTFOLIO
TABLE 136.SHIMADZU CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 137.WATERS CORPORATION: KEY EXECUTIVES
TABLE 138.WATERS CORPORATION: COMPANY SNAPSHOT
TABLE 139.WATERS CORPORATION: OPERATING SEGMENTS
TABLE 140.WATERS CORPORATION: PRODUCT PORTFOLIO
TABLE 141.WATERS CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
LIST OF FIGURES
FIGURE 1.GLOBAL METABOLOMICS MARKET SEGMENTATION
FIGURE 2.GLOBAL METABOLOMICS MARKET
FIGURE 3.SEGMENTATION METABOLOMICS MARKET
FIGURE 4.TOP INVESTMENT POCKET IN METABOLOMICS MARKET
FIGURE 5.TOP WINNING STRATEGIES, 2019-2021*
FIGURE 6.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2019-2021(%)
FIGURE 7.TOP WINNING STRATEGIES, BY COMPANY, 2019-2021*
FIGURE 8.MODERATE BARGAINING POWER OF BUYERS
FIGURE 9.MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 10.MODERATE THREAT OF NEW ENTRANTS
FIGURE 11.LOW THREAT OF SUBSTITUTION
FIGURE 12.HIGH COMPETITIVE RIVALRY
FIGURE 13.TOP PLAYER POSITIONING, 2020
FIGURE 14.MARKET SHARE ANALYSIS, 2020
FIGURE 15.RESTRAINTS AND DRIVERS: METABOLOMICS MARKET
FIGURE 16.METABOLOMICS MARKET SEGMENTATION, BY PRODUCT AND SERVICES
FIGURE 17.METABOLOMICS MARKET FOR METABOLOMICS INSTRUMENTS, BY COUNTRY, 2020-2030 ($MILLION)
FIGURE 18.METABOLOMICS MARKET FOR METABOLOMICS BIOINFORMATICS TOOLS AND SERVICES, BY COUNTRY, 2020-2030 ($MILLION)
FIGURE 19.METABOLOMICS MARKET SEGMENTATION, BY APPLICATION
FIGURE 20.METABOLOMICS MARKET FOR BIOMARKER DISCOVERY, BY COUNTRY, 2020-2030 ($MILLION)
FIGURE 21.METABOLOMICS MARKET FOR DRUG DISCOVERY, BY COUNTRY, 2020-2030 ($MILLION)
FIGURE 22.METABOLOMICS MARKET FOR TOXICOLOGY TESTING, BY COUNTRY, 2020-2030 ($MILLION)
FIGURE 23.METABOLOMICS MARKET FOR NUTRIGENOMICS, BY COUNTRY, 2020-2030 ($MILLION)
FIGURE 24.METABOLOMICS MARKET FOR FUNCTIONAL GENOMICS, BY COUNTRY, 2020-2030 ($MILLION)
FIGURE 25.METABOLOMICS MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2020-2030 ($MILLION)
FIGURE 26.METABOLOMICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2020-2030 ($MILLION)
FIGURE 27.METABOLOMICS MARKET SEGMENTATION, BY INDICATION
FIGURE 28.METABOLOMICS MARKET FOR CANCER, BY COUNTRY, 2020-2030 ($MILLION)
FIGURE 29.METABOLOMICS MARKET FOR CARDIOVASCULAR DISORDERS, BY COUNTRY, 2020-2030 ($MILLION)
FIGURE 30.METABOLOMICS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2020-2030 ($MILLION)
FIGURE 31.METABOLOMICS MARKET FOR INBORN ERRORS OF METABOLISM, BY COUNTRY, 2020-2030 ($MILLION)
FIGURE 32.METABOLOMICS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2020-2030 ($MILLION)
FIGURE 33.AGILENT TECHNOLOGIES, INC.: NET SALES, 2018-2020 ($MILLION)
FIGURE 34.AGILENT TECHNOLOGIES, INC.: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 35.AGILENT TECHNOLOGIES, INC.: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 36.DANAHER CORPORATION: NET SALES, 2018-2020 ($MILLION)
FIGURE 37.DANAHER CORPORATION: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 38.DANAHER CORPORATION: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 39.BIOCRATES LIFE SCIENCES AG: NET SALES, 2018-2020 ($MILLION)
FIGURE 40.BIOCRATES LIFE SCIENCES AG: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 41.BIOCRATES LIFE SCIENCES AG: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 42.BRUKER CORPORATION: NET SALES, 2018-2020 ($MILLION)
FIGURE 43.BRUKER CORPORATION: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 44.BRUKER CORPORATION: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 45.LECO CORPORATION: NET SALES, 2018-2020 ($MILLION)
FIGURE 46.LECO CORPORATION: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 47.LECO CORPORATION: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 48.METABOLON, INC.: NET SALES, 2018-2020 ($MILLION)
FIGURE 49.METABOLON, INC.: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 50.METABOLON, INC.: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 51.HUMAN METABOLOME TECHNOLOGIES, INC.: NET SALES, 2018-2020 ($MILLION)
FIGURE 52.HUMAN METABOLOME TECHNOLOGIES, INC.: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 53.HUMAN METABOLOME TECHNOLOGIES, INC.: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 54.BIO-RAD LABORATORIES, INC.: NET SALES, 2018-2020 ($MILLION)
FIGURE 55.BIO-RAD LABORATORIES, INC.: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 56.BIO-RAD LABORATORIES, INC.: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 57.SHIMADZU CORPORATION: NET SALES, 2018-2020 ($MILLION)
FIGURE 58.SHIMADZU CORPORATION: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 59.SHIMADZU CORPORATION: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 60.WATERS CORPORATION: NET SALES, 2018-2020 ($MILLION)
FIGURE 61.WATERS CORPORATION: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 62.WATERS CORPORATION: REVENUE SHARE, BY REGION, 2020 (%)
This section provides opinions of the top-level CXOs in the biotech & pharmaceutical industry. According to the CXOs, Metabolomics is a rapidly developing branch of medical science that manipulates sophisticated analytical technologies with the application of multi-variant, statistical methods for data interpretation and information extraction to classify and quantify cellular metabolites. In recent years, huge investment was made by private and government entities to develop analytical approaches to examine various cell products such as verities of proteins, metabolites, and gene expressions. These approaches are generally known as “omics” and they are very crucial to comprehend organism biological structure and metabolic activities.
The CXOs further state that, increases in the prevalence of chronic diseases such as cancer diabetes and cardiovascular diseases is leading to growth in acceptance of unorthodox diagnostics tests and development of novel biomarker detection and drug discovery technologies. In addition, rise in demand for personalized medicine and increase in investment in R&D by government and private organizations is expected to generate heavy demand for metabolomics products and services. Metabolomics is expected to cover wider application scope than previously predicted constant development in metabolomic platforms will assist in numerous cell culture applications.
A. The total market value of Metabolomics market is $2,032 million in 2020.
A. The forecast period for metabolomics market is 2021 to 2030
A. The market value of Metabolomics market in 2030 is $6,663 million.
A. The base year is 2020 in Metabolomics market
A. Top companies such as, Agilent Technologies, Inc., Danaher Corporation, Metabolon, Inc., Shimadzu Corporation, and Waters Corporation held a high market position in 2020. These key players held a high market postion owing to the strong geographical foothold in different regions.
A. Metabolomics Bioinformatics segment is expected to account for the largest market share in the year 2020. This is due to a rise in utilization of metabolomics analysis tool and services and rise in need for data management.
A. Metabolomics has the ability to detect a large number of metabolites from fluid or tissue sample in a single step and it also can yield great amounts, which leads to rise in demand for metabolomics thereby driving the growth of the market
A. Asia-Pacific has the highest growth rate in the market which is growing due to the contribution of the following emerging countries such as China with a CAGR of 13.9%.
A. Metabolomics is the study and analysis of the biochemical processes involving intermediates and byproducts of metabolic activities.
Start reading instantly.
This Report and over 67,404+ more Reports, Available with Avenue Library. T&C*.
Enterprise
License/PDF
Library
Membership
*Taxes/Fees, if applicable will be added during checkout. All prices in USD
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
Get Industry Data AlertsTo ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Contact Details
Need to talk to an expert? Book your free consultation and let our research experts help you with your needs/problems.
Global Report 
Regional Report
Country Report
Related Report